Skip to main content
SpringerLink
Log in

Insulin therapy for type 2 diabetes

  • Mini Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Insulin therapy provides effective glycemic control in patients with diabetes who have deficient beta-cell function and insulin secretion. Subjects with type 2 diabetes not adequately controlled on oral agents or incretin therapies can initiate basal insulin replacement to correct fasting hyperglycemia. While all basal insulin preparations have similar efficacy in lowering fasting plasma glucose and improving A1C, the newer basal insulin analogs are associated with a lower risk of hypoglycemia than NPH insulin. Patients whose A1C levels remain above goal despite adequate basal insulin replacement need to evaluate and correct post-prandial hyperglycemia. With progressive beta-cell deficiency, rapid-acting insulin preparations can be introduced before one or more meals and titrated to achieve post-prandial glycemic control. For many patients requiring full basal/bolus insulin replacement, a strategy of fixed prandial insulin doses can yield acceptable glycemic control when compared to a more sophisticated approach utilizing carbohydrate counting and matching to insulin. Concentrated insulin preparations such as U-500 have also been of value in patients with resistant type 2 diabetes. Regardless of the type of insulin replacement used, the blood glucose lowering effects of insulin need to be carefully balanced with the increasing risk of hypoglycemia, and the weight gain associated with insulin intensification.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. B.L. Wajchenberg, Beta-cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 28(2), 187–218 (2007)

    Article  PubMed  CAS  Google Scholar 

  2. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, R. Sherwin, B. Zinman, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1), 193–203 (2009)

    Article  PubMed  CAS  Google Scholar 

  3. R.R. Holman, A.J. Farmer, M.J. Davies, J.C. Levy, J.L. Darbyshire, J.F. Keenan, S.K. Paul, Three-year efficacy of complex insulin regimens in type 2 diabetes. N. Engl. J. Med. 361(18), 1736–1747 (2009)

    Article  PubMed  CAS  Google Scholar 

  4. J.S. Skyler, R. Bergenstal, R.O. Bonow, J. Buse, P. Deedwania, E.A. Gale, B.V. Howard, M.S. Kirkman, M. Kosiborod, P. Reaven, R.S. Sherwin, Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J. Am. Coll. Cardiol. 53(3), 298–304 (2009)

    Article  PubMed  Google Scholar 

  5. I.B. Hirsch, Insulin analogues. N. Engl. J. Med. 352(2), 174–183 (2005)

    Article  PubMed  CAS  Google Scholar 

  6. P. Kurtzhals, Pharmacology of insulin detemir. Endocrinol. Metab. Clin. North Am. 36(Suppl 1), 14–20 (2007)

    Article  PubMed  CAS  Google Scholar 

  7. H.W. Rodbard, L. Blonde, S.S. Braithwaite, E.M. Brett, R.H. Cobin, Y. Handelsman, R. Hellman, P.S. Jellinger, L.G. Jovanovic, P. Levy, J.I. Mechanick, F. Zangeneh, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract. 13(Suppl 1), 1–68 (2007)

    Article  PubMed  Google Scholar 

  8. American Diabetes Association, Standards of medical care in diabetes–2012. Diabetes Care 35(Suppl 1), S11–S63 (2012)

    Google Scholar 

  9. M.C. Riddle, J. Rosenstock, J. Gerich, The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26(11), 3080–3086 (2003)

    Article  PubMed  CAS  Google Scholar 

  10. J. Rosenstock, M. Davies, P.D. Home, J. Larsen, C. Koenen, G. Schernthaner, A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51(3), 408–416 (2008)

    Article  PubMed  CAS  Google Scholar 

  11. A. Philis-Tsimikas, Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes. Patient Prefer. Adherence 2, 323–332 (2008)

    Article  PubMed  Google Scholar 

  12. M. Lepore, S. Pampanelli, C. Fanelli, F. Porcellati, L. Bartocci, A. Di Vincenzo, C. Cordoni, E. Costa, P. Brunetti, G.B. Bolli, Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49(12), 2142–2148 (2000)

    Article  PubMed  CAS  Google Scholar 

  13. T. Heise, L. Nosek, B.B. Ronn, L. Endahl, L. Heinemann, C. Kapitza, E. Draeger, Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with Type 1 diabetes. Diabetes 53, 1614–1620 (2004)

    Article  PubMed  CAS  Google Scholar 

  14. F. Porcellati, P. Rossetti, N.R. Busciantella, S. Marzotti, P. Lucidi, S. Luzio, D.R. Owens, G.B. Bolli, C.G. Fanelli, Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 30(10), 2447–2452 (2007)

    Article  PubMed  CAS  Google Scholar 

  15. O. Klein, J. Lynge, L. Endahl, B. Damholt, L. Nosek, T. Heise, Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes. Metab. 9(3), 290–299 (2007)

    Article  PubMed  CAS  Google Scholar 

  16. K. Horvath, K. Jeitler, A. Berghold, S.H. Ebrahim, T.W. Gratzer, J. Plank, T. Kaiser, T.R. Pieber, A. Siebenhofer, Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2, CD005613 (2007)

  17. S.G. Swinnen, A.C. Simon, F. Holleman, J.B. Hoekstra, J.H. Devries, Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 7, CD006383 (2011)

  18. J. Plank, A. Siebenhofer, A. Berghold, K. Jeitler, K. Horvath, P. Mrak, T.R. Pieber, Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch. Intern. Med. 165(12), 1337–1344 (2005)

    Article  PubMed  CAS  Google Scholar 

  19. P.D. Home, The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes. Metab. 14(9), 780–788 (2012)

    Article  PubMed  CAS  Google Scholar 

  20. G. Schernthaner, W. Wein, N. Shnawa, P.C. Bates, M.A. Birkett, Preprandial vs. postprandial insulin lispro-a comparative crossover trial in patients with Type 1 diabetes. Diabet. Med. 21(3), 279–284 (2004)

    Article  PubMed  CAS  Google Scholar 

  21. S.K. Garg, J. Rosenstock, K. Ways, Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr. Pract. 11(1), 11–17 (2005)

    Article  PubMed  Google Scholar 

  22. T. Danne, J. Aman, E. Schober, D. Deiss, J.L. Jacobsen, H.H. Friberg, L.H. Jensen, A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 26(8), 2359–2364 (2003)

    Article  PubMed  CAS  Google Scholar 

  23. M. Gagnon-Auger, P. du Souich, J.P. Baillargeon, E. Martin, P. Brassard, J. Menard, J.L. Ardilouze, Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care 33(12), 2502–2507 (2010)

    Article  PubMed  CAS  Google Scholar 

  24. Y. Handelsman, J.I. Mechanick, L. Blonde, G. Grunberger, Z.T. Bloomgarden, G.A. Bray, S. Dagogo-Jack, J.A. Davidson, D. Einhorn, O. Ganda, A.J. Garber, I.B. Hirsch, E.S. Horton, F. Ismail-Beigi, P.S. Jellinger, K.L. Jones, L. Jovanovic, H. Lebovitz, P. Levy, E.S. Moghissi, E.A. Orzeck, A.I. Vinik, K.L. Wyne, American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr. Pract. 17(Suppl 2), 1–53 (2011)

    Article  PubMed  Google Scholar 

  25. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycemia in Type 2 Diabetes: a patient-centered approach. Diabetes Care 35(6), 1364–1379 (2012)

    Article  PubMed  CAS  Google Scholar 

  26. R.R. Holman, K.I. Thorne, A.J. Farmer, M.J. Davies, J.F. Keenan, S. Paul, J.C. Levy, Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N. Engl. J. Med. 357(17), 1716–1730 (2007)

    Article  PubMed  CAS  Google Scholar 

  27. A. Philis-Tsimikas, G. Charpentier, P. Clauson, G.M. Ravn, V.L. Roberts, B. Thorsteinsson, Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin. Ther. 28(10), 1569–1581 (2006)

    Article  PubMed  CAS  Google Scholar 

  28. M. Davies, F. Storms, S. Shutler, M. Bianchi-Biscay, R. Gomis, Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28(6), 1282–1288 (2005)

    Article  PubMed  CAS  Google Scholar 

  29. L. Blonde, M. Merilainen, V. Karwe, P. Raskin, Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes. Metab. 11(6), 623–631 (2009)

    Article  PubMed  CAS  Google Scholar 

  30. L. Meneghini, C. Koenen, W. Weng, J.L. Selam, The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes–results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes. Metab. 9(6), 902–913 (2007)

    Article  PubMed  CAS  Google Scholar 

  31. A. Fritsche, M.A. Schweitzer, H.U. Haring, Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med. 138(12), 952–959 (2003)

    Article  PubMed  CAS  Google Scholar 

  32. H. Yokoyama, J. Tada, F. Kamikawa, S. Kanno, Y. Yokota, M. Kuramitsu, Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res. Clin. Pract. 73(1), 35–40 (2006)

    Article  PubMed  CAS  Google Scholar 

  33. H.U. Janka, G. Plewe, K. Busch, Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J. Am. Geriatr. Soc. 55(2), 182–188 (2007)

    Article  PubMed  Google Scholar 

  34. H.U. Janka, G. Plewe, M.C. Riddle, C. Kliebe-Frisch, M.A. Schweitzer, H. Yki-Jarvinen, Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28(2), 254–259 (2005)

    Article  PubMed  CAS  Google Scholar 

  35. A.H. Barnett, B. Charbonnel, M. Donovan, D. Fleming, R. Chen, Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr. Med. Res. Opin. 28(4), 513–523 (2012)

    Article  PubMed  CAS  Google Scholar 

  36. T. Vilsboll, J. Rosenstock, H. Yki-Jarvinen, W.T. Cefalu, Y. Chen, E. Luo, B. Musser, P.J. Andryuk, Y. Ling, K.D. Kaufman, J.M. Amatruda, S.S. Engel, L. Katz, Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes. Metab. 12(2), 167–177 (2010)

    Article  PubMed  CAS  Google Scholar 

  37. M. Riddle, R. Pencek, S. Charenkavanich, K. Lutz, K. Wilhelm, L. Porter, Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 32(9), 1577–1582 (2009)

    Article  PubMed  CAS  Google Scholar 

  38. P.A. Levin, J.H. Mersey, S. Zhou, L.A. Bromberger, Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr. Pract. 18(1), 17–25 (2012)

    Article  PubMed  Google Scholar 

  39. J.B. Buse, R.M. Bergenstal, L.C. Glass, C.R. Heilmann, M.S. Lewis, A.Y. Kwan, B.J. Hoogwerf, J. Rosenstock, Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154(2), 103–112 (2011)

    Article  PubMed  Google Scholar 

  40. P. Raskin, E. Allen, P. Hollander, A. Lewin, R.A. Gabbay, P. Hu, B. Bode, A. Garber, Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28(2), 260–265 (2005)

    Article  PubMed  CAS  Google Scholar 

  41. J. Rosenstock, A.J. Ahmann, G. Colon, J. Scism-Bacon, H. Jiang, S. Martin, Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 31(1), 20–25 (2008)

    Article  PubMed  CAS  Google Scholar 

  42. A. Liebl, R. Prager, K. Binz, M. Kaiser, R. Bergenstal, B. Gallwitz, Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes Obes. Metab. 11(1), 45–52 (2009)

    Article  PubMed  CAS  Google Scholar 

  43. L. Meneghini, H. Mersebach, S. Kumar, A.L. Svendsen, K. Hermansen, Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr. Pract. 17(5), 727–736 (2011)

    Article  PubMed  Google Scholar 

  44. M.R. Lankisch, K.C. Ferlinz, J.L. Leahy, W.A. Scherbaum, Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes. Metab. 10(12), 1178–1185 (2008)

    PubMed  CAS  Google Scholar 

  45. M.B. Davidson, P. Raskin, R.J. Tanenberg, A. Vlajnic, P. Hollander, A stepwise approach to insulin therapy in patients with type 2 diabetes failing basal insulin treatment. Endocr. Pract. 17(3), 395–405 (2011)

    Article  PubMed  Google Scholar 

  46. I.B. Hirsch, R.M. Bergenstal, C.G. Parkin, E. Wright, J.B. Buse, A real-world approach to insulin therapy in primary care practice. Clin. Diabetes 23(2), 78–86 (2005)

    Article  Google Scholar 

  47. L.F. Meneghini, K. Hermansen, H. Mersebach, A.L. Svendsen, S. Kumar, Treatment in-tensification by stepwise addition of prandial insulin aspart to once-daily basal insulin detemir in subjects with type 2 diabetes: the STEPwise™ trial. Diabetes 59(Supplement 1), A199 (2010)

    Google Scholar 

  48. R.M. Bergenstal, M. Johnson, M.A. Powers, A. Wynne, A. Vlajnic, P. Hollander, M. Rendell, Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 31(7), 1305–1310 (2008)

    Article  PubMed  CAS  Google Scholar 

  49. A. de la Pena, M. Riddle, L.A. Morrow, H.H. Jiang, H. Linnebjerg, A. Scott, K.M. Win, M. Hompesch, K.F. Mace, J.G. Jacobson, J.A. Jackson, Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care 34(12), 2496–2501 (2011)

    Article  PubMed  Google Scholar 

  50. S.L. Quinn, M.C. Lansang, D. Mina, Safety and effectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus. Pharmacotherapy 31(7), 695–702 (2011)

    Article  PubMed  CAS  Google Scholar 

  51. W.S. Wafa, M.I. Khan, Use of U-500 regular insulin in type 2 diabetes. Diabetes Care 29(9), 2175–2176 (2006)

    Article  PubMed  Google Scholar 

  52. P. Ballani, M.T. Tran, M.D. Navar, M.B. Davidson, Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care 29(11), 2504–2505 (2006)

    Article  PubMed  CAS  Google Scholar 

  53. J.M. Neal, Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy. Endocr. Pract. 11(5), 305–307 (2005)

    Article  PubMed  Google Scholar 

  54. UK Hypoglycemia Study Group, Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50(6), 1140–1147 (2007)

    Article  Google Scholar 

  55. H.C. Gerstein, M.E. Miller, R.P. Byington, D.C. Goff Jr, J.T. Bigger, J.B. Buse, W.C. Cushman, S. Genuth, F. Ismail-Beigi, R.H. Grimm Jr, J.L. Probstfield, D.G. Simons-Morton, W.T. Friedewald, Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358(24), 2545–2559 (2008)

    Article  PubMed  CAS  Google Scholar 

  56. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, P.D. Reaven, F.J. Zieve, J. Marks, S.N. Davis, R. Hayward, S.R. Warren, S. Goldman, M. McCarren, M.E. Vitek, W.G. Henderson, G.D. Huang, Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360(2), 129–139 (2009)

    Article  PubMed  CAS  Google Scholar 

  57. M.C. Riddle, W.T. Ambrosius, D.J. Brillon, J.B. Buse, R.P. Byington, R.M. Cohen, D.C. Goff Jr, S. Malozowski, K.L. Margolis, J.L. Probstfield, A. Schnall, E.R. Seaquist, Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33(5), 983–990 (2010)

    Article  PubMed  Google Scholar 

  58. M.E. Miller, D.E. Bonds, H.C. Gerstein, E.R. Seaquist, R.M. Bergenstal, J. Calles-Escandon, R.D. Childress, T.E. Craven, R.M. Cuddihy, G. Dailey, M.N. Feinglos, F. Ismail-Beigi, J.F. Largay, P.J. O’Connor, T. Paul, P.J. Savage, U.K. Schubart, A. Sood, S. Genuth, The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 340, b5444 (2010)

    Article  PubMed  Google Scholar 

  59. J.S. Skyler, R. Bergenstal, R.O. Bonow, J. Buse, P. Deedwania, E.A. Gale, B.V. Howard, M.S. Kirkman, M. Kosiborod, P. Reaven, R.S. Sherwin, Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32(1), 187–192 (2009)

    Article  PubMed  Google Scholar 

  60. S. Zoungas, J. Chalmers, T. Ninomiya, Q. Li, M.E. Cooper, S. Colagiuri, G. Fulcher, B.E. de Galan, S. Harrap, P. Hamet, S. Heller, S. Macmahon, M. Marre, N. Poulter, F. Travert, A. Patel, B. Neal, M. Woodward, Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55(3), 636–643 (2012)

    Article  PubMed  CAS  Google Scholar 

  61. L.F. Meneghini, B. Miranda-Palma, Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes. Expert Rev. Endocr. Metab. 7(1), 9–14 (2012)

    Article  CAS  Google Scholar 

Download references

Disclosure

L. Meneghini is on the Advisory Board/Panel of Novo Nordisk; he is also the Consultant for Novo Nordisk and sanofi-aventis. Grant/Research Support were provided by MannKind, Pfizer, and Boehringer Ingelheim.

Author information

Authors and Affiliations

  1. University of Miami Miller School of Medicine, 1450 NW 10th Ave, Miami, FL, 33136, USA

    Luigi F. Meneghini

Authors
  1. Luigi F. Meneghini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luigi F. Meneghini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meneghini, L.F. Insulin therapy for type 2 diabetes. Endocrine 43, 529–534 (2013). https://doi.org/10.1007/s12020-012-9817-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-012-9817-6

Keywords

Search

Navigation